19th Sep 2013 07:18
LONDON (Alliance News) - Skyepharma PLC Thursday said its development partner Mundipharma has started an intentional clinical trial of flutiform, which treats chronic obstructive pulmonary disease.
The oral-and-inhalation drug delivery company said the aim of the study is to demonstrate the superiority of the efficacy of flutiform over formoterol in a pressurised-metered dose inhaler
Formoterol is used together with other medicines to treat asthma and prevent bronchospasm in patients with asthma.
Flutiform has already been approved for the treatment of bronchial asthma in 21 European countries, as well as in Israel, Australia and Hong Kong. It is currently marketed for the treatment of bronchial asthma in 12 European countries.
It is not currently indicated for chronic obstructive pulmonary disease.
Skyepharma shares were quoted at 78.45 pence, down 3.8%.
By Anthony Tshibangu; [email protected]; @AnthonyAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
SKP.L